Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer

J. C. Wilson*, L. J. Murray, C. M. Hughes, A. Black, L. A. Anderson

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Citations (Scopus)
1 Downloads (Pure)

Abstract

Background:

Evidence for non-steroidal anti-inflammatory drugs (NSAIDs) preventing head and neck cancer (HNC) is inconclusive; however, there is some suggestion that aspirin may exert a protective effect.

Methods:

Using data from the United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined the association between aspirin and ibuprofen use and HNC.

Results:

Regular aspirin use was associated with a significant 22% reduction in HNC risk. No association was observed with regular ibuprofen use.

Conclusion:

Aspirin may have potential as a chemopreventive agent for HNC, but further investigation is warranted.

Original languageEnglish
Pages (from-to)1178-1181
Number of pages4
JournalBritish Journal of Cancer
Volume108
Issue number5
Early online date28 Feb 2013
DOIs
Publication statusPublished - 19 Mar 2013

Keywords

  • aspirin
  • cohort study
  • head and neck cancer
  • ibuprofen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer'. Together they form a unique fingerprint.

  • Cite this